NanoPitch: Driving Health Innovation

NanoPitch: Driving Health Innovation

Invitation to NanoPitch: Driving Health Innovation | Thursday 11 May | 5pm - 7:30pm

By The University of Sydney Nano Institute

Date and time

Thu, 11 May 2023 5:00 PM - 7:30 PM AEST

Location

Level 3, Messel Lecture Theatre, Sydney Nanoscience Hub (Building A31)

Physics Road Camperdown, NSW 2050 Australia

About this event

Invitation to NanoPitch: Driving Health Innovation | Thursday 11 May | 5pm - 7:30pm

Get inspired by the next big ideas for health innovation

The University of Sydney Nano Institute's researchers are striving to make nanotechnology part of the solution to everyday problems. In health care, nanotechnology can improve outcomes for patients and save lives. At this event, Sydney Nano researchers will pitch their ideas to a panel of expert judges to find possible partners to increase the impact of their work. This event will focus on key health areas including MedTech, Pharma, and BioTech, followed by a networking session with drinks and canapes.

Join this event on Thurs 11 May from 5pm to listen to the latest advances in nanotechnology that are driving health innovation at the University of Sydney. By attending this event, you will:

  • Be the first to hear about the latest innovations coming out of the University of Sydney
  • Have the opportunity to network with the presenters, researchers, and industry
  • Learn the art of pitching
  • Find your next research and commercialisation partners

____

Event details

  • When: Thursday 11 May, 2023
  • Time: 5pm - 7:30pm (The event will commence with pitches followed by networking opportunities)
  • Where: Messel Lecture Theatre (4002), Sydney Nanoscience Hub (Building A31), Physics Rd, The University of Sydney
  • This event will be held in person only.
  • Light refreshments and drinks will be served.
  • Please RSVP by Thursday 4 May for catering purposes.

____

Pitches

  • Prof. Vesna Miletic (Faculty of Medicine and Health (FMH)) - New biocompatible dental materials
  • A/Prof. Ann Kwan (Faculty of Science) - Biocompatible coating for 3D printed implants
  • Dr. Md Mahbub Hassan (Faculty of Engineering) - Nanohydrogel for cellular and ocular therapies
  • Dr. Hien Duong (FMH) - Bacteriophage nanobots
  • Dr. Matthew Griffith (Faculty of Engineering) - Development of the affordable artificial retina
  • Dr. Clara Tran (Faculty of Engineering) - Plasma surface coating for Novel ImmunoDiagnostics platforms
  • A/Prof. Stefano Palomba (Faculty of Science) - Mobile sensing for improved diagnostic and cancer detection
  • Mr. Matt Hadden (Faculty of Engineering) - Determining the Nanomechanical signature of human pathological tissues using advance analytical and bioengineering tools

Note: Program subject to change without notice

____

Judges

  • Prof Tony Weiss | McCaughey Chair in Biochemistry, NHMRC Leadership Fellow, and Professor of Biochemistry and Molecular Biotechnology | Tony founded the biotechnology clinical stage company Elastagen Pty Ltd which was sold to Allergan/AbbVie in one of the largest transactions ever completed in the Australian life science sector. He was recently awarded the Prime Minister's Prize for Innovation, the NSW Premier's Prize for Science and Engineering Leadership in Innovation, and the Eureka Prize for Innovation in Medical Research. He is also the President of the Tissue Engineering and Regenerative Medicine International Society (TERMIS).
  • Prof Julie Cairney | Pro Vice-Chancellor (Research - Enterprise and Engagements) | Julie is the Pro Vice-Chancellor (Research Enterprise and Engagement) at the University of Sydney. A Graduate of the Australian Institute of Company Directors, she serves on the Boards of the NSW Defence Innovation Network and the NSW Smart Sensing Network. She is also the CEO of Microscopy Australia, a national infrastructure project that provides open-access microscopy infrastructure across Australia.
  • Dr John Kurek | Investment Manager at Uniseed | John is the Biotechnology Investment Manager at Uniseed, Australia's longest running venture fund. At Uniseed John is responsible for identifying new investment opportunities and covers Uniseed's overall biotechnology and life sciences portfolio. His experience extends from drug discovery to the clinical phase of drug development. He has acted as a Director on the Board of investee companies that have collectively raised AU$300 million.

Organised by

Sales Ended